Building off Pfizer investment, microbiome-focused Vedanta expands new fundraise to launch 2 studies
A little more than six months after winning an endorsement from Pfizer for its IBD microbiome program, Vedanta Biosciences is ready to step on the gas.
Vedanta wrapped up a $68 million Series D raise Wednesday morning, which included the $25 million equity investment Pfizer plunked down back in January. With the biotech content with its early-stage results and manufacturing capabilities, Vedanta is getting ready to potentially launch multiple mid- to late-stage studies and needed the extra cash, CEO Bernat Olle tells Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.